National Health (April 2022 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2022

Overview

The National Health (April 2022 First New Brand Statutory Price Reduction) (Exercise of Ministerial Discretion) Determination 2022 was enacted to provide a framework for the exercise of ministerial discretion under the National Health Act 1953. This determination specifically addresses the statutory price reduction for the first new brand of pharmaceutical item as of April 2022. The enactment by the Department of Health, under the authority of the Minister for Health and Aged Care, aims to ensure that the pricing of pharmaceutical items aligns with national health policies and objectives. The policy objective of this determination is to maintain a stable and predictable pharmaceutical pricing environment, which supports equitable access to essential medications for the Australian public. The determination was issued by Nikolai Tsyganov, Acting Assistant Secretary of the Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and it came into effect on 1 April 2022. It specifically identifies the brand of pharmaceutical item, in this case, Lacosamide Oral Solution 10 mg per mL, 200 mL, for which the approved ex-manufacturer price will not be reduced by any percentage, thus maintaining the existing pricing structure for this particular drug. This legislative instrument is instrumental in upholding the integrity of the national health pricing policies, ensuring that the pricing decisions are made in accordance with the broader objectives of the National Health Act 1953.

Scope and Application

The National Health (April 2022 First New Brand Statutory Price Reduction) (Exercise of Ministerial Discretion) Determination 2022 applies to the approved ex-manufacturer price of specific pharmaceutical brands, as outlined in Schedule 1. This instrument is made under subsection 99ACF(3AA) of the National Health Act 1953 and is specifically designed to address the pricing of pharmaceutical items listed in the schedule. The determination sets out the approved ex-manufacturer price for the specified brand of Lacosamide, an oral solution, for the purposes of subsection 99ACF(2AB) of the Act. It is a Commonwealth instrument and applies nationally across Australia, impacting entities involved in the manufacturing, supply, and distribution of pharmaceutical products within the healthcare sector. There are no stated exclusions, exemptions, or thresholds in this particular determination, and its application is strictly confined to the pharmaceutical items listed in Schedule 1. The determination is effective from 1 April 2022, and its scope does not extend beyond the specified brands and prices as outlined in the instrument.

Key Provisions

The National Health (April 2022 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2022 is a statutory instrument under subsection 99ACF(3AA) of the National Health Act 1953. It comes into effect on 1 April 2022 and specifies that the approved ex-manufacturer price for certain pharmaceutical items will not be subject to a statutory price reduction. According to section 5 of the determination, the approved ex-manufacturer price for the brand of pharmaceutical item specified in the table in Schedule 1, namely Lacosamide Oral solution 10 mg per mL, 200 mL, will not undergo any percentage reduction. Entities and parties governed by this determination must ensure compliance with the specified price reduction provisions. Specifically, they must adhere to the instruction that the approved ex-manufacturer price of the designated pharmaceutical item, Lacosamide, is not to be reduced. This requirement applies to the pharmaceutical item listed in Schedule 1, ensuring that the price remains unchanged as per the ministerial discretion exercised in this determination. Breach of the provisions outlined in this determination could lead to regulatory consequences. While specific offences, penalties, or consequences are not detailed in the text, non-compliance with statutory requirements under the National Health Act 1953 can typically result in fines or other enforcement actions. The maximum penalties for such breaches can vary based on the severity and nature of the non-compliance, as defined in the overarching legislation.